CTOs on the Move

Pyxis Oncology

www.pyxisoncology.com

 
Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Stephen Monks
 Chief Technology Officer Profile

Funding

Pyxis Oncology raised $22M on 07/17/2019

Similar Companies

OraPharma , Inc.

OraPharma , Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

CNS Therapeutics

CNS Therapeutics is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AGC Biologics

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.

Apthera

Apthera, Inc. is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Fulcrum Therapeutics

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum`s proprietary product engine, FulcrumSeekâ„¢, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.